In veterinary parenteral manufacturing, lidocaine hydrochloride monohydrate is selected over the free base because the base requires alkaline pH for aqueous solubility and becomes unstable during terminal sterilization. A standard 20 mg/mL injectable solution is compounded by dissolving the API at 20–25°C in Water for Injection under a nitrogen overlay in a 316L stainless steel jacketed vessel, followed by pH adjustment to 5.0–6.0 with 0.1 N hydrochloric acid or sodium hydroxide. Tonicity is adjusted with sodium chloride to 285–310 mOsmol/kg before membrane filtration through a 0.22 µm PVDF cartridge; for multi-dose vials, preservative loading of methylparaben 1.0 mg/mL and propylparaben 0.1 mg/mL is introduced before final volume. Terminal sterilization in Type I borosilicate glass vials at 121°C for 15 min produces an Fo ≥ 12.0, but production lines must confirm that headspace oxygen is below 0.5% v/v to limit oxidative discoloration. The degradation marker 2,6-dimethylaniline is monitored per the current lidocaine hydrochloride monograph; accumulation above 0.01% triggers batch rejection in several regulatory jurisdictions. Container closure integrity testing follows USP <1207> with helium leak rate ≤ 1.4 × 10⁻⁶ mbar·L/s for vial formats. Sterility is verified per USP <71>, bacterial endotoxins per USP <85> with a limit calculated as K/M, and sub-visible particulates per USP <788> using light obscuration with limits of not more than 6000 particles ≥10 µm and 600 particles ≥25 µm per container for small-volume formats. Automatic piston filling lines hold fill volume tolerance at ±1.5%. The end product is a ready-to-inject local anesthetic solution for infiltration and perineural administration in cattle, horses, dogs, and cats, with batch records documenting pre-filtration bioburden below 10 CFU/100 mL before sterile filtration under 21 CFR 211.63 and 211.67.

What Particle Fraction Governs Direct Compression of Lidocaine HCl Tablets Without Punch Sticking?

Direct compression of lidocaine hydrochloride tablets begins with a laser-diffraction particle size profile in which the d90 is controlled below 250 µm and the d10 is maintained above 30 µm to reduce segregation and die-fill variation. The API is blended with microcrystalline cellulose 102, spray-dried lactose monohydrate, crospovidone at 2.0 wt%, and magnesium stearate at 0.5 wt% in a diffusion blender operating at 20 rpm for 15 min; the final blend is sampled at 10 points per USP <905> and must show an acceptance value not exceeding 15.0. Tablet compression is performed on a rotary press with 8–15 kN compression force, producing hardness of 50–80 N, friability below 1.0% according to USP <1216>, and disintegration under 15 min in water at 37°C per USP <701>. For local oral delivery, the matrix remains in the buccal space rather than relying on systemic absorption; hepatic first-pass extraction would otherwise remove the drug before therapeutic plasma levels are reached. Dissolution testing follows USP <711> Apparatus 2 with 900 mL phosphate buffer pH 6.8 at 50 rpm, with sampling at 15 min, 30 min, 45 min, and 60 min. Published data for systemic veterinary oral lidocaine tablets is limited because of substantial first-pass metabolism, so the oral solid format is produced chiefly for prescribed local mucosal application where a metered solid dose is required. Batch records must include in-process checks under 21 CFR 211.110 for blend uniformity, and tablet presses are fitted with vacuum dedusting to keep residual die-wall lubricant below the level that retards dissolution. Punch and die surfaces receive a chromium nitride coating to reduce sticking when compacting lidocaine hydrochloride at relative humidity above 45%.

In automated dosator-type capsule fillers, lidocaine hydrochloride powder must flow through a 14 mm dosing tube without plugging; therefore the preblend is dry-milled until the conditioned bulk density remains between 0.45 g/mL and 0.65 g/mL and the Hausner ratio stays below 1.35. Hard gelatin capsules of size 3 or 4 are filled to 120–180 mg total mass, with API ratios typically between 5 wt% and 20 wt% on lactose monohydrate or pregelatinized starch carriers; talc at 0.5 wt% and colloidal silicon dioxide at 0.2 wt% are added as glidant and anti-adherent. Fill weight uniformity is measured per USP <905> with an acceptance value ≤ 15.0, and shell moisture is maintained at 13.0–16.0% w/w during storage because shells below 12.0% become brittle and above 18.0% risk stickiness on high-speed machines. Capsule processing is conducted at 40–50% RH and 20–25°C; humidity above 55% RH can initiate shell crosslinking if residual aldehydes from lactose impurities are present. Dissolution is tested in 0.1 N hydrochloric acid at 37°C per USP <711>, with Q set at 80% in 30 min where compendial or customer specification requires. The encapsulated product is typically intended for local oral cavity anesthesia or for extemporaneous repackaging into veterinary hospital kits, rather than as a first-line systemic dosage form because of substantial hepatic first-pass metabolism after swallowing. Line clearance under 21 CFR 211.67 is critical when the same encapsulation suite handles multiple lidocaine salts or other amide anesthetics; cross-contact with ester-type anesthetics must be segregated by dedicated product-contact parts and validated cleaning procedures using swab limits below 10 ppm of the prior active.

Powders Must Stay Below 1.0% Loss on Drying to Prevent Caking and Sticking in Veterinary Dispensing

Dry powder applications for lidocaine hydrochloride in veterinary medicine separate into oral reconstitution powders and topical dusting preparations. In oral reconstitution powders, the API is co-milled with lactose monohydrate or mannitol until d90 is ≤ 150 µm and moisture by Karl Fischer remains ≤ 1.0%; higher moisture levels create liquid bridging during storage and alter reconstitution time. A V-shell blender with intensifier bar is operated at 25 rpm for 20 min after a geometric dilution of 1:10 and 1:100 to distribute the active fraction; blend uniformity is tested at 10 sampling points with relative standard deviation ≤ 5.0% per USP <905>. Bulk powder is filled into multi-dose polypropylene bottles with desiccant canisters and induction-seal liners; fill weight tolerance is set at ±3.0% on gravimetric fillers. Reconstitution directions are validated to achieve a target concentration between 10 mg/mL and 20 mg/mL depending on label claim; for example, a product labeled to contain 500 mg per sachet reconstituted to 25 mL yields 20 mg/mL. The pH must remain between 5.0 and 7.0 after reconstitution to limit amide hydrolysis. Topical dusting powders are prepared with 1.0–5.0 wt% lidocaine hydrochloride in an absorbable starch base, passed through a 0.250 mm screen, and controlled for microbial limits per USP <61> and USP <62>. Because lidocaine hydrochloride shows significant moisture uptake under RH > 60%, airtight closures and silica gel desiccants are required; stability chambers monitor 25°C/60% RH and 40°C/75% RH per ICH Q1A guidelines. The finished powder product is intended for measured reconstitution in farm or clinic settings, where cold-chain storage is not advised because freezing of reconstituted solutions can cause salt precipitation.

At 50–60°C fluid-bed inlet air, lidocaine hydrochloride granules must be dried to a loss-on-drying of 1.0–2.0% before final sieving because residual water above 2.5% slows dissolution and can promote the formation of 2,6-dimethylaniline during prolonged storage. High-shear granulation is carried out in a 10 L vertical granulator with impeller speed 200 rpm and chopper speed 1500 rpm; a 5% w/w povidone K30 binder solution is added at 2.5–3.0 wt% dry binder relative to the dry powder mass, with total water addition of 8–12 wt%. Wet massing is terminated when the motor current rises 15–20% above the dry-mix baseline, which correlates with granule mean size of 150–250 µm and avoids over-granulation that would compress the dissolution profile. Drying is performed in a top-spray fluid-bed unit with inlet air at 60°C and product temperature held at 38–42°C; inlet dew point is controlled below 5°C to avoid surface rehydration. Dried granules are passed through 0.8 mm and 1.6 mm screens, and fines below 125 µm are re-granulated at no more than 20% of the batch size to prevent granule friability drift. Final blend uniformity is measured per USP <905>, and dissolution under USP <711> Apparatus 1 at 100 rpm in 900 mL pH 6.8 phosphate buffer requires Q = 75% at 45 min where specified. The granulated product is filled into sachets or unit-dose cups for reconstitution as an oral rinse or for mixing into a soft feed carrier immediately before administration; the finished granules are protected from light because lidocaine hydrochloride degrades more rapidly in clear packaging under UV stress. Equipment contact surfaces are 316L stainless steel with Ra ≤ 0.8 µm polish to reduce adherence of wet mass during discharge.

Premix Carriers and the Limit of Moisture-Induced Segregation

Medicated feed premixes containing lidocaine hydrochloride are manufactured under a stepwise dilution protocol; the active fraction is first blended with a cohesive carrier such as rice hulls, calcium carbonate, or spray-dried lactose at a 1:10 ratio, then diluted again to 1:100 before being added to the final feed matrix. A horizontal ribbon mixer is operated at 50–70% of gross capacity with a tip speed of 1.0 m/s to minimize dead zones; mixing time of 10–15 min is established by homogeneity testing, with 10 thief samples requiring relative standard deviation ≤ 10.0% for final feed and ≤ 5.0% for the premix intermediate. Carrier selection is dominated by moisture uptake: calcium carbonate tolerates RH ≤ 60% without caking, whereas rice hulls require drying to 6–9% moisture before use. Dust control is achieved by adding 0.5–1.0 wt% of food-grade mineral oil or vegetable oil to the carrier before active blending, which also reduces electrostatic segregation of fine lidocaine particles. Blended premix is packed in multi-wall paper bags with a moisture barrier liner; labels carry batch numbers and instruction for in-feed inclusion rates calculated by a pharmacist or veterinarian. Cross-contamination control follows 21 CFR 211.67 and, where applicable, local veterinary feed regulations; dedicated mixers are required because amide anesthetics can retain in ribbon seals. The finished premix is intended for mixing into solid feed or milk replacer under prescription, but published data for systemic efficacy of orally administered lidocaine in production animals is limited, and the oral route is not used where plasma concentrations are required due to first-pass extraction. If the premix is freshly mixed in liquid feed, the pH must remain below 7.0 and the holding time not exceed 2 h to avoid hydrolysis of the amide bond.

Because lidocaine hydrochloride is freely soluble in water, ready-to-use veterinary oral and topical solutions can be produced without co-solvents, but preservative dissolution and viscosity development dictate the mixing sequence. The API is dissolved in purified water at 20–25°C in a 316L stainless steel vessel with an overhead stirrer at 120 rpm; sodium benzoate at 0.1% w/v or potassium sorbate at 0.1% w/v is added after the API has fully dissolved, and pH is adjusted to 5.0–6.5 with 0.1 N hydrochloric acid. Viscosity modifiers such as carboxymethylcellulose sodium at 0.5–1.0% w/v are hydrated separately and mixed under vacuum to avoid air entrapment; the final solution is passed through a 0.45 µm polypropylene filter before filling into amber PET bottles with tamper-evident closures. Preservative efficacy is tested per USP <51>, microbial enumeration per USP <61>, absence of specified microorganisms per USP <62>, and pH stability over 12 months at 25°C/60% RH. The finished solution is designed for metered oral or topical application to mucous membranes in companion animals, with fill volume accuracy of ±2.0% on peristaltic fill lines. Because light exposure accelerates amide degradation, the solution is filled in amber or opaque packaging; exposure to open air during dosing is limited by pump closures that minimize headspace oxygen ingress. Alkaline buffers are intentionally omitted because pH above 7.0 increases the hydrolysis rate and reduces shelf life. The batch record requires final assay by HPLC with UV detection at 254 nm, using a C18 column, with system suitability per the relevant lidocaine hydrochloride monograph.